ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

Separately, BTIG Research initiated coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 target price for the company.

ImmunityBio Trading Down 4.7 %

Shares of NASDAQ IBRX opened at $2.86 on Friday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.11 and a beta of 0.94. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The business has a 50 day simple moving average of $3.01 and a 200-day simple moving average of $3.75.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Stephens Inc. AR acquired a new position in ImmunityBio during the 4th quarter valued at approximately $26,000. Captrust Financial Advisors bought a new stake in ImmunityBio in the third quarter valued at $41,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio during the fourth quarter valued at $35,000. Virtu Financial LLC bought a new position in shares of ImmunityBio during the third quarter worth about $51,000. Finally, Maia Wealth LLC acquired a new stake in shares of ImmunityBio in the 4th quarter worth about $37,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.